NASDAQ: STIMNeuronetics Inc Stock
$3.88+0.12 (+3.19%)
Updated Apr 21, 2025
STIM Price
$3.88
Fair Value Price
N/A
Market Cap
$255.36M
52 Week Low
$0.52
52 Week High
$5.92
P/E
-2.81x
P/B
9.22x
P/S
0.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$74.89M
Earnings
-$43.71M
Gross Margin
72.3%
Operating Margin
-48.63%
Profit Margin
-58.4%
Debt to Equity
3.94
Operating Cash Flow
-$31M
Beta
1.44
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
STIM Overview
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STIM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important STIM news, forecast changes, insider trades & much more!
STIM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STIM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STIM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STIM is poor value based on its book value relative to its share price (9.22x), compared to the US Diagnostics & Research industry average (3.22x)
P/B vs Industry Valuation
STIM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STIM due diligence checks available for Premium users.
Valuation
STIM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.81x
Industry
35.03x
Market
27.14x
STIM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.22x
Industry
3.22x
STIM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STIM's financial health
Profit margin
Revenue
$22.5M
Net Income
-$12.7M
Profit Margin
-56.3%
STIM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STIM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$140.9M
Liabilities
$109.1M
Debt to equity
3.94
STIM's short-term assets ($58.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STIM's long-term liabilities ($77.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STIM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STIM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.6M
Investing
-$2.4M
Financing
$9.6M
STIM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STIM vs Diagnostic & Research Stocks
Neuronetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.